A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

Completed · Phase 1 · Has a placebo group

Conditions studied: COVID-19

In brief

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.

Key facts

Study ID
NCT04411628
Run by
Eli Lilly and Company
People needed
26
Starts
2020-05-28
Expected to finish
2020-08-26
Last updated by the study team
2021-11-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.